Form 4: Agilon Health Director to Receive Significant RSU Grant Under Pre-Arranged Plan

Agilon Health, Inc. director Sharad Mansukani is set to acquire 78,724 restricted stock units (RSUs) on May 28, 2025, as part of a pre-arranged Rule 10b5-1 plan.

Summary

• Sharad Mansukani, a Director of agilon health, inc. (AGL), will acquire 78,724 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition is May 28, 2025, and it is being made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction.
• The RSUs were acquired at a price of $0 per share, which is typical for equity grants.
• These restricted stock units will vest in full on May 28, 2026, contingent upon Mr. Mansukani's continued service as a director.
• Following this reported transaction, Sharad Mansukani's beneficial ownership will total 1,352,757 shares, which includes other restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU grant aligns the director's interests with shareholders and is a standard, transparent compensation practice.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction is conducted under a Rule 10b5-1 plan, which indicates a pre-arranged, transparent, and compliant approach to insider equity transactions, reducing concerns about opportunistic trading.

Risks

• The vesting of the 78,724 restricted stock units is subject to Sharad Mansukani's continued service as a director until May 28, 2026, meaning the grant could be forfeited if service ceases before this date.

Future Outlook

The future outlook for this specific transaction involves the vesting of the granted Restricted Stock Units on May 28, 2026, contingent on the director's continued service.

Industry Context

The grant of Restricted Stock Units (RSUs) to directors is a common practice in the healthcare and broader corporate sectors, serving as a key component of executive and director compensation packages. This method aligns the interests of the board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a standard practice across various industries, including healthcare, aligning with global benchmarks for corporate governance and incentive structures.
• The vesting schedule, tied to continued service, is typical for RSU grants to ensure retention and long-term commitment from board members.
• The acquisition price of $0 for RSUs is standard, as these represent a grant of future equity rather than a purchase.

Corporate Governance

Related Party Transactions

• The acquisition of Restricted Stock Units by Sharad Mansukani, a director of agilon health, inc., constitutes a related party transaction as it involves an equity grant from the company to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with those of shareholders, potentially leading to more focused efforts on long-term stock performance.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The 78,724 Restricted Stock Units are scheduled to vest in full on May 28, 2026, subject to Sharad Mansukani's continued service as a director.

Key Dates

Keywords

agilon health, AGL, Sharad Mansukani, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Rule 10b5-1 Plan